Neurotensin and its high affinity receptor (NTSR1) localise within dopaminergic neurones in the mesocortical, mesolimbic and nigrostriatal systems [1] [2] [3] [4] [5] and it is now clear that neurotensin can selectively modulate dopaminergic neurotransmission. 2, 3, [6] [7] [8] [9] [10] [11] This has led to the hypothesis that altered neurotensin function contributes to the pathogenesis of schizophrenia and other psychoses. This hypothesis has been supported circumstantially by a number of lines of evidence. (1) Central administration of neurotensin produces effects similar to those produced by the peripheral administration of atypical antipsychotics.
(3) Reduced numbers of neurotensin receptors in the brains of schizophrenics. 18, 19 Given the above link between neurotensin and dopamine, and the evidence implicating altered neurotensin function in psychosis, we 20 have postulated that DNA sequence variation in neurotensin or its receptors might be associated with schizophrenia. In keeping with this hypothesis, an association has recently been reported 21 between schizophrenia and the gene encoding the neurotensin high affinity receptor (NTSR1). However, caution is required because the associated marker, a tetranucleotide repeat, is located 3 kb away from the 3Ј end of the gene and there is no evidence that it is functional. Therefore, as a follow-up to our earlier work on neurotensin, 20 we have now sought to test the hypothesis that DNA sequence variants that alter the structure or expression of the NTSR1 gene (VAPSEs) 22 are associated with schizophrenia. However, while we found 14 novel sequence variants in 28 probands with psychosis, none resulted in an amino acid change, and neither direct nor indirect association studies suggested these are involved in susceptibility to schizophrenia. Molecular Psychiatry (2000) 5, 552-557.
NTSR1 is a single copy gene that maps to chromosome 20q13, and comprises four exons spanning more than 10 kb. 23 Its product, NTSR1, is the only one of the three known neurotensin receptors which has yet been cloned in humans. 4 In order to identify VAPSEs we used denaturing high performance liquid chromatography 24 to screen 4648 bases of NTSR1 (including all four exons) as well as 772 bases of the promoter region.
DHPLC analysis revealed a total of 14 different heteroduplex formations in eight different PCR fragments. Sequencing identified these as: CϾT at NTSR1+909, TϾC at NTSR1+1615, CϾT at NTSR1+1793, GϾA at NTSR1+2319, CϾT at NTSR1+2092, GϾA at NTSR1+2501, AϾG at NTSR1+2909, TϾC at NTSR1+3020, two TϾC polymorphisms at NTSR1+3096 and NTSR1+3215, GϾA at NTSR1+3083, GϾA at NTSR1+3496, CϾT at NTSR1+3523, and a T insertion at NTSR1+3450. Seven of these variants (NTSR1+909, 2319, 2092, 2909, 3020, 3215, 3496) altered restriction digestion sites and were therefore confirmed by this tertiary method (details of all enzymes available on request). The seven polymorphisms that did not alter restriction sites (NTSR1+1615, 1793, 2501, 3096, 3083, 3523, 3450) were confirmed by sequencing PCR products in both directions. Unfortunately, the full genomic sequence data have not been deposited in GenBank, and therefore the descriptions of the polymorphisms are given relative to the ATG translation start codon according to Le and colleagues 1997. 23 Only one polymorphism, NTSR1+909CϾT, was found within the coding sequence of the gene. However, this polymorphism which is within exon 2 does not change the amino acid sequence of the protein product. The remaining 13 polymorphisms were all located within the 3Ј UTR. Because this is not a coding region, it is impossible to predict if any of these are likely to have functional effects based upon their sequence, but it is at least possible that they potentially exert an effect on mRNA stability, or regulate rates of transcription or translation.
In order to test the hypothesis that polymorphisms in NTSR1 might contribute to the aetiology of schizophrenia, a case-control sample was genotyped for representative polymorphisms using restriction digestion assay systems. The NTSR1+909CϾT polymorphism was chosen because although it is unlikely to be a VAPSE, it was the only polymorphism present in the coding region of the gene. Also, for the purpose of linkage disequilibrium (LD) analysis, it was also the most 5Ј polymorphism found. Because all other polymorphisms were located within a segment of less than 2000 bases and were not clear candidate VAPSEs, only two variants (NTSR1+3020TϾC and NTSR1+3496GϾA) were tested. Even under fairly conservative assumptions, selecting two markers to represent 2000 bases should be adequate to detect putative effects of the other adjacent variants by LD. 25 The two particular 3Ј UTR polymorphisms were chosen for LD analysis because, in the initial screen, they were the most polymorphic markers and were the simplest to genotype by restriction digestion.
Allele frequencies were not significantly different in the patient group as compared to the controls for the NTSR1+909 polymorphism (patients n = 374, allele C n = 354, allele T = 20; controls n = 460, allele C = 430, allele T = 30: 2 = 0.505, 1 df, P = 0.478), the NTSR1+3020 polymorphism (patients n = 346, allele T = 309, allele C = 37; controls n = 460, allele T = 396, allele C = 64: = 0.721, 2 df, P = 0.697) were not significantly different in the patients as compared to the controls. Also, no differences were found when cells with rare genotypes were collapsed with other genotypes (data not shown). Genotype frequencies were not significantly different from Hardy-Weinberg expectation.
To incorporate information from all markers simultaneously, we performed haplotype analysis using the computer program HAPMAX (available at http://www.uwcm.ac.uk/uwcm/mg/download) which estimates haplotype frequencies for multiple markers using an EM algorithm to allow for phase unknowns. No evidence was found for association of the disorder with haplotypes constructed from all three markers ( 2 = 3.826, 7 df, P = 0.7995), nor was there any evidence for association of the disorder with pairwise haplotypes (data not shown). To estimate LD between the markers, we used HAPMAX to estimate haplotype frequencies in the combined samples of patients and controls. Not surprisingly given their proximity, the markers were all found to be in LD. NTSR1+3020/909, DЈ = 0.68, . Our failure to detect any clear VAPSEs in this gene, or to detect association between affected status and individual markers, genotypes or haplotypes does not support the hypothesis that DNA sequence variations in NTSR1 contribute to susceptibility to schizophrenia. However, this conclusion depends upon the sensitivity of our sequence variation detection procedure, the power of our screening sample, and the power of the study for exclusion of genetic effects.
We have previously shown that our protocol for DHPLC analysis is extremely sensitive for detecting Molecular Psychiatry sequence variants, 26, 27 and it is therefore unlikely that there are sequence variants in our screening set that we have failed to detect. Secondly, under the null hypothesis that there are no polymorphisms in NTSR1 associated with psychosis, our screening panel of 28 patients has a power of 0.95 to detect polymorphisms occurring in the general population with a frequency of 5%. Therefore, it is unlikely that we have missed even fairly uncommon alleles in this study, although these results only reflect findings from the UK Caucasian population. Finally for the polymorphisms in NTSR1+909, NTSR1+3020, and NTSR1+3496 respectively, the upper limit of the 95% confidence interval for the OR (alleles T, C, and A) is 1.365, 1.257, and 1.278 respectively. Thus, at least in our population, we can exclude rather small effects of these polymorphisms on susceptibility to schizophrenia.
We conclude therefore that within the constraints mentioned above, our data suggest that polymorphisms in NTSR1 do not contribute to the aetiology of schizophrenia. However the sequence variations in NTSR1 we report here are candidate polymorphisms for other disorders in which disturbances in dopamine neurotransmission are suspected, including Parkinson's disease, bipolar disorder, ADHD and substance abuse.
Material and methods

PCR
NTSR1 was amplified as 15 separate PCR fragments. The 5Ј flanking region was amplified as two fragments p1 and p2 (Table 1) . Exons 2 and 3 were each amplified individually, while exon 1 was represented in four fragments (1a, 1b, 1c and 1d) and exon 4 was represented in nine fragments (4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h and 4i). Excluding primer sequences, this includes a total of 4648 bases of the gene and 772 bases of 5Ј flanking region. The sample for comparative sequencing consisted of 28 patients with functional psychosis (14 patients meeting DSM-IV criteria for schizophrenia and 14 patients meeting DSM-IV criteria for bipolar disorder). PCR amplification took place using a Hybaid PCR Express Thermocycler (Hybaid, Middlesex, UK) in a volume of 25 l containing 40 ng of genomic DNA, 20 pmol of each primer, 100 m dNTPs, and 1 unit of either Taq Polymerase (Qiagen, Crawley, UK), Taq Gold (Perkin Elmer Applied Biosystems, Cheshire, UK), or Deep Vent (exo-) DNA polymerase (New England Biolabs, Herts, UK) in the appropriate buffer as supplied by the manufacturer. Deep Vent (exo-) DNA polymerase was used for PCR programmes A-C, Taq Gold was used for PCR programme D, and Taq Polymerase was used for PCR programmes E-I (see Table 2 ). The primers, fragment sizes, DHPLC oven temperatures and analytic gradients are detailed in Table 1 , PCR conditions are given in Table 2 . Prior to HPLC analysis, the PCR products were denatured by heating to 96°C for 2 min, and were then allowed to reanneal by cooling to 55°C over 41 min. : GCC AGC TTT TTC AAC TGC TT  4e  4eL: GGC TGA GGC ACA GAC TCA TT  G  397  62  58-68  4eR: TTC TCA GAC GGG GAA ACT G  4f  4fL: GGC TGC CTG CAC CGG CCA TGT CG  A  414  62  59-69  4fR: GGC AGC AAA GCT CTT CCG CCC AGA GCA  4g  4gL: CCT CCC AGT GCC CAA GGG CCA CCA  A  478  62  60-70  4gR: CCC CGCCCC AGA GAC CCC ACG TC  4h  4hL: GTC TCT CAG GAT GGT GCT CT  I  395  58  64-74  4hR: TTG AGA GAT ACA CGG GGT TT  63  58-68  4i  4iL: ACA GCC CTC ACA GCT CAA A  G  382  62  57-67  4iR: GAA GTT CAG GAG ACG GTG AG  p1  p1L: TGC TGG GGC GCA GGC TCT CAG G  A  590  62  64-74  p1R: CCC CAG CCC TGG GCT CGC TCA GTT  p2  p2L: GGG GGC CCC TGG GCA ACC CAA A  B  249  62 54-64 p2R: TGA GAG CCT GCG CCC CAG CAG GAT T Detection of polymorphisms DHPLC was performed as described in detail elsewhere. 26, 27 Column temperature for DHPLC analysis was determined using software that is available free of charge over the internet (http://insertion.stanford.edu/ melt.html). 27 To ensure maximum sensitivity, in addition to the temperature suggested by the software (n°C), each fragment was also run at n + 2°C. 27 It should be noted that because some fragments have multiple melt domains they are run at more than two temperatures. Where DHPLC analysis suggested that a subject was heterozygous, the PCR products from that individual were sequenced to determine the nature of the polymorphism using the Big Dye Terminator Cycle Sequencing Kit (Perkin Elmer Applied Biosystems, Cheshire, UK) as described by the manufacturer.
DNA samples
The case control study was undertaken using 203 unrelated Caucasians born in the UK or Ireland meeting DSM-IV 28 criteria for schizophrenia. These comprised a single member of 138 affected sib-pairs ascertained through mental health services and relatives support groups in England and Wales and 65 unrelated individuals recruited from inpatient and daypatient facilities in South Wales. There were 144 males and 59 females. Diagnoses were determined following a semi-structured interview and examination of case notes as described. 29 Local Research Ethics Committee approval was obtained, and subjects gave written informed consent to participate. A total of 230 control individuals were group matched to probands for age, sex, and ethnicity from more than 1400 blood donors recruited from the local branch of the National Blood Transfusion Service (Wales). Controls were not specifically screened for the absence of psychiatric illness, 30 although the policy of the National Blood Transfusion Service is not to receive donations from individuals who are on medication. 
Genotyping
Genotyping was performed by restriction digestion of PCR products. The NTSR1+909 polymorphism was genotyped (amplified using primer pair 2, see Table 1 ) using Hha1 (New England Biolabs) and the conditions recommended by the manufacturer. This produced fragments of 225 bp and 30 bp where there was a C at the polymorphic site, and a single fragment of 255 bp in the presence of a T. The NTSR1+3020 polymorphism was genotyped (having been amplified using primer pair 4f, see Table 1 ) using Sac1 (New England Biolabs) and the conditions recommended by the manufacturer. This produced fragments of 373 bp and 41 bp where there was a T at the polymorphic site, and a fragment of 414 bp when there was a C at this site. The NTSR1+3496 polymorphism was genotyped (having been amplified using primer pair 4 h, see Table  1 ) using BsmF1 (New England Biolabs) and the conditions recommended by the manufacturer. This produced fragments of 164 bp and 231 bp where there was a G at the polymorphic site, and a fragment of 395 bp when there was an A at this site. In each case the digestion products were visualised on 1.5% agarose gels.
Statistical analysis
Association between schizophrenia and candidate polymorphisms was tested by 2 . Haplotype and marker-marker LD analyses were undertaken using the computer program HAPMAX (M. Krawczak: http://www.uwcm.ac.uk/uwcm/mg/download). This program employs an EM algorithm to allow for phase unknowns. 31 The resulting maximum likelihood estimates of haplotype frequencies were tested for differences making use of the fact that twice the log-likelihood difference between the models involved approximately follows a 2 -distribution. The DЈ estimate of LD 32 was calculated from the HAPMAX estimated haplotype frequencies. DЈ is the difference between the observed haplotypes and that expected under independence, divided by the maximum difference that could be achieved given the observed allele frequencies. 32 ORs were calculated by Jwoolf programme (software written and kindly provided by P McGuffin and J Williams).
